<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578732</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 318</org_study_id>
    <nct_id>NCT02578732</nct_id>
  </id_info>
  <brief_title>FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial</brief_title>
  <official_title>BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>howard safran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to&#xD;
      FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated&#xD;
      with the ability to administer at least 10 cycles of therapy. Investigators therefore will&#xD;
      evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See summary above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.</measure>
    <time_frame>Until progression, up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A</measure>
    <time_frame>During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXA</intervention_name>
    <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
    <arm_group_label>FOLFOXA</arm_group_label>
    <other_name>FOLFOXA is a combination treatment including: Abraxane, Oxaliplatin, Leucovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically or cytologically confirmed pancreatic ductal adenocarcinoma. Patients&#xD;
             with pathology or cytology showing carcinoma of pancreas or adenosquamous of the&#xD;
             pancreas are also eligible.&#xD;
&#xD;
          -  Locally advanced pancreatic cancer, including patients defined by Callery19 as&#xD;
             &quot;unresectable&quot; and &quot;borderline resectable&quot; are eligible:&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1&#xD;
&#xD;
          -  No prior chemotherapy for pancreatic cancer.&#xD;
&#xD;
          -  No major surgery within 3 weeks of the start of study treatment. Patients must have&#xD;
             recovered from the side effects of any major surgery at the start of study treatment.&#xD;
             For questions on if a surgery is deemed &quot;major,&quot; definition by surgeon can be used for&#xD;
             clarification. Laparoscopy and central venous catheter placement are not considered&#xD;
             major surgery.&#xD;
&#xD;
          -  No prior invasive malignancy within the prior two years. However, patients with an&#xD;
             early stage malignancy that is not expected to require treatment in the next 2 years&#xD;
             (such as early stage, resected breast cancer or asymptomatic prostate cancer) are&#xD;
             eligible.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Not pregnant and not nursing. Women of child bearing potential must have a negative&#xD;
             serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG)&#xD;
             within 7 days prior to beginning of treatment. Post-menopausal women (surgical&#xD;
             menopause or lack of menses &gt;24 months) do not need to have a pregnancy test, please&#xD;
             document status.&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males must use an effective&#xD;
             contraception method 28 days prior to treatment, during treatment and for three months&#xD;
             after completing treatment (men are to use contraception for six months post last dose&#xD;
             of drug). Documentation of this being discussed required.&#xD;
&#xD;
          -  Required Initial Laboratory Values:&#xD;
&#xD;
               -  Neutrophils ≥ 1,500/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3 (transfusion independent, defined as not receiving&#xD;
                  platelet transfusions within 7 days prior to laboratory sample)&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0g/dL&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL -or- creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Total bilirubin &lt;1. 5 x ULN&#xD;
&#xD;
               -  AST (SGOT) &amp; ALT (SGPT) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.5xULN. (Patients with elevated alkaline phosphatase,&#xD;
                  total bilirubin, AST and ALT, who have subsequently undergone biliary stenting&#xD;
                  and their liver tests are improving, do not need to wait for their alkaline&#xD;
                  phosphatase to become &lt; 2.5x ULN if their total bilirubin, AST and ALT have&#xD;
                  improved to within required study levels and the alkaline phosphatase is&#xD;
                  decreasing.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic disease&#xD;
&#xD;
          -  Prior hypersensitivity to Oxaliplatin or Abraxane ® that in the investigators opinion&#xD;
             would put the patient at risk if re-exposed&#xD;
&#xD;
          -  Preexisting neuropathy is not allowed from any cause.&#xD;
&#xD;
          -  Patients with serious medical risk factors involving any of the major organ systems&#xD;
             such that the investigator considers it unsafe for the patient to receive FOLFOX-A&#xD;
&#xD;
          -  Patients with unstable biliary stents or with plastic stents. Information on type of&#xD;
             stent is required at registration.&#xD;
&#xD;
          -  Patients with active infection or fever (patients on antibiotics for infection or&#xD;
             patients getting over a cold or seasonal virus are not excluded), or known historical&#xD;
             or active infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Patients with active sepsis or pneumonitis.&#xD;
&#xD;
          -  Patients with a history of interstitial lung disease, history of slowly progressive&#xD;
             dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis,&#xD;
             pulmonary hypersensitivity pneumonitis or multiple allergies that in the&#xD;
             investigator's opinion would put the patient at an increased risk.&#xD;
&#xD;
          -  Uncontrolled diabetes. If patient has diabetes, confirmation on status (controlled or&#xD;
             uncontrolled) required at registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BrUOG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhode Island Hospital and The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903/02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>August 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02578732/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FOLFOXA</title>
          <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOLFOXA</title>
          <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="47" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.</title>
        <time_frame>Until progression, up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FOLFOXA</title>
            <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A</title>
        <time_frame>During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until 30 days after the last dose of FOLFOX-A, up to 28 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FOLFOXA</title>
          <description>Schema:&#xD;
1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**&#xD;
Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.&#xD;
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)&#xD;
It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment&#xD;
Antiemetics will be administered as per standard institutional policy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder, other</sub_title>
                <description>Takotsubo cardiomyopathy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Elevated AST/ALT</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Safran, MD</name_or_title>
      <organization>Brown University Oncology Research Group</organization>
      <phone>401-863-300</phone>
      <email>BrUOG@BROWN.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

